Clinical trials: Liver Inflammation
Hepatitis C
A Study of Grazoprevir (MK-5172) in Hepatitis C-Infected Male Participants (MK-5172-004)
This multiple dose study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of grazoprevir (MK-5172) in Genotype (GT) 1 and GT3 Hepatitis C virus (HCV)- infected participants.
- Trial name
- NCT00998985
- Testing
- Grazoprevir
- Volunteers
- 91 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis D, Chronic, Hepatitis B, Chronic
Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection (Study P04603)
The objective of this study is to determine the effectiveness of peginterferon alfa-2b 1.5 mcg/kg/week administered for 52 weeks (wk) in previously untreated participants coinfected with hepatitis virus B and D.
- Trial name
- NCT00686790
- Testing
- Peginterferon alfa-2b (PegIntron, SCH 54031)
- Volunteers
- 68 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Hepatitis C, Hepatitis C Virus
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy
The purpose of this study is to assess the efficacy and safety of ABT-493 and ABT-530 with or without ribavirin (RBV) in participants with chronic hepatitis C virus, (HCV)-infection who previously failed treatment with a direct…
- Conditions
- Chronic Hepatitis C, Hepatitis C Virus, HCV, Direct-Acting Antiviral Agent (DAA)-Experienced
- Trial name
- NCT02446717
- Testing
- ABT-493, ABT-530, ribavirin (RBV), ABT-493/ABT-530
- Volunteers
- 141 people
- Sponsor
- AbbVie
Alcoholic Hepatitis
A Research Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DUR-928 in Patients With Alcoholic Hepatitis
This is a research trial testing DUR-928 (an experimental medication). The purpose of this trial is to assess the dose related safety, Pharmacokinetics, and Pharmacodynamics of DUR 928 in patients with moderate and severe…
- Trial name
- AH (NCT03432260)
- Testing
- DUR-928 30 mg, DUR-928 90 mg, DUR-928 150 mg
- Where
- 7 sites in United States
- Volunteers
- 19 people
- Sponsor
- Durect
Hepatitis B
Ledipasvir/Sofosbuvir for Hepatitis B Virus Infection
The goals of therapy against chronic hepatitis B are to decrease the morbidity and mortality related to chronic HBV infection. Currently available antiviral therapy can suppress viral replication but only a small proportion…
- Trial name
- APOSTLE (NCT03312023)
- Testing
- Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni], Sofosbuvir 400 MG [Sovaldi], Ledipasvir 90 MG
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Maryland, Baltimore
Hepatitis C Virus, Advanced Fibrosis
Study of Long-term Peg Intron vs. Colchicine in Non-responders.
In this study Peg-Intron will be tested to see if it will give better results than Colchicine. At this time, there is currently no recommended maintenance treatment for patients who have failed to respond to…
- Conditions
- Hepatitis C Virus, Advanced Fibrosis, Cirrhosis
- Trial name
- COPILOT (NCT00179413)
- Testing
- PEG -Intron, Colchicine
- Where
- 49 sites in United States
- Volunteers
- 549 people
- Sponsor
- Beth Israel Deaconess Medical Center
Hepatitis C Virus Infection
Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of sofosbuvir /velpatasvir (SOF/VEL) fixed-dose combination (FDC) in participants with chronic hepatitis C virus (HCV) who have received…
- Trial name
- NCT02781571
- Testing
- SOF/VEL
- Where
- 15 sites in Spain, Switzerland and 1 more
- Volunteers
- 79 people
- Sponsor
- Gilead Sciences
Hepatitis C, Chronic
A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response
This study will evaluate the efficacy and safety of peginterferon alfa-2a 40KD + ribavirin combination therapy given for 24 weeks versus 48 weeks in patients with chronic hepatitis C, genotype 2/3.
- Trial name
- NCT00623428
- Testing
- peginterferon alfa-2a, Ribavirin
- Where
- 101 sites in United States, Australia and 8 more
- Volunteers
- 235 people
- Sponsor
- Hoffmann-La Roche
Type 1 Diabetes Mellitus
Adherence to Guidelines VAccination in Type 1 DIabetes Mellitus Patients (AVADI-1).
Observational study about adherence to guidelines for Influenza, Pneumococcal and Hepatitis B Vaccination in adult patients with type 1 Diabetes mellitus.
- Trial name
- AVADI-1 (NCT03478254)
- Testing
- Influenza vaccination, Pneumococcal vaccination, Hepatitis B Virus (HBV) vaccination
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Jesús Moreno Fernández
Hepatitis C
An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection
The purpose of this study is to evaluate the activity and safety of telaprevir on Hepatitis C Virus (HCV) Genotype 4, alone or in combination with standard therapy, that is, pegylated-interferon-alfa-2a and ribavirin in…
- Trial name
- NCT00580801
- Testing
- Telaprevir, Pegylated-interferon-alfa-2a, Ribavirin
- Volunteers
- 24 people
- Sponsor
- Tibotec BVBA
Hepatitis B Vaccines
Lot-to-lot Consistency of Sci-B-Vac™ in Adults
A Controlled Trial to Assess the Lot-to-lot Consistency of Sci-B-Vac™ in Adults
- Trial name
- NCT03408730
- Testing
- Hepatitis B Vaccination
- Where
- 26 sites in United States, Belgium and 4 more
- Volunteers
- 2,838 people, healthy volunteers welcome
- Sponsor
- VBI Vaccines Inc.
Hepatitis A
A Study to Evaluate the Safety and Immunogenicity of the Hepatitis A Virus Vaccine HAVpur in Healthy Young Children
This is a study to test whether vaccination with HAVpur Junior against hepatitis A provides protection that is non-inferior to the protection afforded by vaccination with Havrix 720 Junior.
- Trial name
- NCT01349829
- Testing
- HAVpur Junior, Havrix 720 Junior
- Where
- 3 sites in India
- Volunteers
- 251 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Hepatitis C
Drug Interaction Study With BI 201335 and Methadone or Buprenorphine/Naloxone
Otherwise healthy subjects who are currently bein maintained on either methadone or buprenorphine/naloxone for opioid maintenance therapy who have been on a stable dose for at least 30 days will be administered BI 201335 daily to…
- Trial name
- NCT01637922
- Testing
- BI 201335
- Where
- 3 sites in United States
- Volunteers
- 34 people
- Sponsor
- Boehringer Ingelheim
Hepatitis C
A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)
This is a study of the safety and efficacy of grazoprevir (MK-5172) in combination with elbasvir (MK-8742) ± ribavirin (RBV). The primary efficacy endpoint will be Sustained Virologic Response 12 weeks after the end of all study…
- Trial name
- C-WORTHy (NCT01717326)
- Testing
- Grazoprevir, Elbasvir, Ribavirin
- Volunteers
- 573 people
- Sponsor
- Merck Sharp & Dohme LLC
Infections, Meningococcal
Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study
This study will be conducted in three stages. In the DTP booster stage at 15 to 24 months of age, all subjects will receive a booster dose of Tritanrix™-HepB/Hiberix™.
- Trial name
- NCT00291343
- Testing
- Tritanrix™- HepB, Hiberix™, Mencevax™ ACWY
- Where
- 2 sites in Philippines
- Volunteers
- 296 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis C Infection
A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults
The purpose of this study is to evaluate the safety and efficacy of ABT-450, ritonavir and ABT-267 (ABT-450/r/ABT-267; ABT-267 also known as ombitasvir) and ABT-333 (also known as dasabuvir) co-administered with ribavirin (RBV)…
- Trial name
- NCT01715415
- Testing
- ABT-450/r/ABT-267, ABT-333, Ribavirin
- Volunteers
- 395 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hepatitis B, Chronic
A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection
The purpose of this study is to evaluate the efficacy of 48-week study intervention with JNJ-73763989+JNJ-56136379+nucleos(t)ide analog (NA) regimen compared to NA alone assessed by HBsAg levels.
- Trial name
- NCT04129554
- Testing
- JNJ-73763989, JNJ-56136379, Entecavir (ETV) monohydrate
- Where
- 41 sites in Belgium, France and 5 more
- Volunteers
- 130 people
- Sponsor
- Janssen Sciences Ireland UC
Hepatitis B, Chronic
A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus Infection
The purpose of this study is to establish the dose-response relationship for antiviral activity of 3 dose levels of JNJ-73763989+nucleos(t)ide analog (NA) and to evaluate the efficacy of combination regimens of JNJ-73763989+NA…
- Trial name
- REEF-1 (NCT03982186)
- Testing
- JNJ-73763989, JNJ-56136379, Nucleos(t)ide Analog (NA)
- Where
- 108 sites in United States, Belgium and 17 more
- Volunteers
- 471 people
- Sponsor
- Janssen Sciences Ireland UC
Hepatitis C, Chronic
A Study of TMC435 in Genotype 1, Hepatitis C-infected Patients Who Relapsed After Previous Interferon (IFN)-Based Therapy
The purpose of this study is to evaluate the efficacy and safety of TMC435 in combination with peginterferon alfa-2a (PegIFNα-2a) and ribavirin in genotype 1 hepatitis C virus (HCV)-infected participants who relapsed after…
- Trial name
- NCT01290731
- Testing
- TMC435, Pegylated interferon (pegIFN alpha-2a), Ribavirin (RBV)
- Where
- 10 sites in Japan
- Volunteers
- 49 people
- Sponsor
- Janssen Pharmaceutical K.K.
Hepatitis C
Phase 3 Study of Sofosbuvir and Ribavirin
This study was to assess the safety and efficacy of sofosbuvir (GS-7977; PSI-7977) in combination with ribavirin (RBV) administered for 12 weeks compared with pegylated interferon (PEG)/RBV administered for 24 weeks in…
- Trial name
- FISSION (NCT01497366)
- Testing
- Sofosbuvir, PEG, RBV
- Where
- 97 sites in United States, Australia and 6 more
- Volunteers
- 527 people
- Sponsor
- Gilead Sciences